Author: Newsdesk

Posted on

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky

Time-Sensitive: Allegations Focus on Overstated REZOLVE-AA Trial Integrity and Prospects

NEW YORK–(BUSINESS WIRE)–Levi & Korsinsky, LLP alerts investors in Nektar Therapeutics (NASDAQ: NKTR) of a pending securities class action. Class Period: February 26, 2025 through December 15, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at [email protected] | (212) 363-7500.

Nektar shares fell $4.14 per share, or 7.77%, closing at $49.16 on December 16, 2025, after the Company disclosed that its Phase 2b REZOLVE-AA trial narrowly missed statistical significance on its primary endpoint. The Court has set May 5, 2026 as the deadline to apply for lead plaintiff appointment.

How Alleged Protocol Failures Undermined the Trial’s Stated Prospects

The lawsuit asserts that throughout the Class Period, management repeatedly portrayed the REZOLVE-AA trial as rigorously conducted, with enrollment criteria carefully designed to screen out ineligible patients. Statements emphasized that only patients with severe-to-very-severe alopecia areata confirmed by SALT scores at both screening and randomization were included, and that patients with unstable disease courses or inadequate washout periods were excluded.

As alleged, these representations painted a misleading picture of the trial’s overall integrity and commercial prospects. The action claims that management knew or recklessly disregarded that enrollment had not followed the stated protocol standards, meaning the trial’s prospects for achieving statistical significance were overstated.

Why Trial Integrity Allegedly Matters to Investors

For a clinical-stage biopharmaceutical company like Nektar, the perceived integrity of a pivotal trial is directly tied to the company’s valuation. The lawsuit contends that by overstating the REZOLVE-AA trial’s prospects, management artificially inflated NKTR’s stock price during the Class Period. Key allegations include:

  • Management described “unique operational features” designed to “minimize clinical operational risk” while four patients with major eligibility violations had been randomized into the trial
  • The Company raised approximately $115 million in a July 2025 public offering while the trial’s integrity was allegedly compromised
  • Two patients had unstable alopecia areata diagnosed less than six months before randomization, a standard exclusion criterion management repeatedly cited as enforced
  • Two additional patients began treatment before completing the prerequisite 8-week washout period for prior medications
  • When the four ineligible patients were excluded from analysis, both treatment arms achieved statistical significance, underscoring how their inclusion skewed the reported results
  • Annual bonuses for senior leadership were tied in part to maintaining REZOLVE-AA enrollment timelines, creating alleged motive to overlook protocol deviations

Speak with an attorney about recovering damages or call (212) 363-7500.

“Investors deserve transparency about material risks that could affect their investments. When a company’s lead clinical trial is the primary driver of shareholder value, the integrity of that trial’s enrollment process is not a minor operational detail — it is material information.” — Joseph E. Levi, Esq.

WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

SMCI Investor Alert: Super Micro Computer Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Diverting AI Servers Illegally: Levi & Korsinsky

SMCI Investor Alert: Super Micro Computer Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Diverting AI Servers Illegally: Levi & Korsinsky

Important Notice Regarding Alleged Export Control Violation Misrepresentations

NEW YORK–(BUSINESS WIRE)–
The artificial intelligence server market attracted tens of billions in capital as investors poured into companies powering next-generation AI infrastructure. Super Micro Computer, Inc. (NASDAQ: SMCI) rode this wave to nearly $15 billion in fiscal 2024 revenue and $22 billion in fiscal 2025, but a federal indictment now alleges approximately $2.5 billion of those sales were illegal. Levi & Korsinsky, LLP notifies investors in Super Micro Computer, Inc. (NASDAQ: SMCI) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between April 30, 2024 and March 19, 2026. Find out if you qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Shares plummeted $10.26, or 33.3%, to close at $20.53 on March 20, 2026 after the U.S. Justice Department unsealed an indictment alleging a conspiracy to divert massive quantities of restricted AI servers to China. Applications to serve as lead plaintiff must be filed by May 25, 2026.

The Alleged Export Control Diversion Methodology

The lawsuit contends that Super Micro’s co-founder and Taiwan-based management orchestrated a scheme to systematically bypass U.S. Department of Commerce licensing requirements for servers containing Nvidia’s most advanced AI chips. According to the DOJ, a third-party broker served as a “fixer” to route approximately $2.5 billion worth of restricted servers to customers in China between 2024 and 2025, all to drive sales and generate revenue in violation of U.S. law.

How Illegal Server Sales Allegedly Inflated Reported Financials

The action claims that throughout the Class Period, the Company attributed its extraordinary revenue growth to “strong demand for AI rack scale PnP solutions” and “innovative DLC designs” while concealing that a material portion of sales depended on illegal exports. The Company’s SEC filings described revenue increases as driven by “demand from customers for GPU servers, HPC, and rack-scale solutions” without disclosing the unlawful China channel.

Key Export Control Allegations for Shareholders

  • The complaint alleges three individuals associated with Super Micro, including co-founder Yih-Shyan Liaw, conspired to divert restricted AI servers to China without required Commerce Department licenses

  • An estimated $2.5 billion in server sales between 2024 and 2025 were allegedly made in violation of U.S. export control laws

  • The Company’s internal controls over export compliance allegedly contained material weaknesses that were not disclosed to investors

  • Quarterly and annual SEC filings attributed sales growth to legitimate demand drivers while allegedly omitting the illegal China diversion channel

  • Super Micro’s risk factor disclosures warned generically that employees “may engage in improper conduct” while the alleged scheme was already underway

Speak with an attorney about recovering damages or call (212) 363-7500.

The Nvidia GPU Factor

The servers at the center of the alleged scheme contained Nvidia’s most advanced AI chips, which have been subject to strict U.S. export controls barring sale to China. The Company acknowledged in SEC filings that these GPU-based servers were “generally more complex and of higher value, resulting in an increase of average selling prices.” The lawsuit contends this higher-value product line was the very category being illegally diverted.

“This case presents important questions about export compliance disclosure obligations in the AI infrastructure sector. When a company’s revenue growth depends in significant part on sales that allegedly violate federal law, investors deserve to know.” — Joseph E. Levi, Esq.

Submit your information to join this case or contact Joseph E. Levi, Esq. at (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report. Applications to serve as lead plaintiff must be filed by May 25, 2026.

Frequently Asked Questions About the SMCI Lawsuit

Q: What is the SMCI class action lawsuit about? A: A securities class action has been filed against Super Micro Computer, Inc. (NASDAQ: SMCI) alleging materially false and misleading statements between April 30, 2024 and March 19, 2026. Shares fell approximately 33.3% after the U.S. Justice Department unsealed an indictment revealing an alleged scheme to illegally divert $2.5 billion in AI servers to China, causing significant losses for shareholders.

Q: Who is eligible to join the SMCI investor lawsuit? A: Investors who purchased SMCI stock or securities between April 30, 2024 and March 19, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did SMCI stock drop? A: Shares fell approximately 33.3%, a decline of $10.26 per share, after the DOJ announced the unsealing of an indictment alleging a conspiracy to divert restricted AI servers to China. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my SMCI shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What do SMCI investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

TCOM Investor Alert: Trip.com Group Limited Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Monopoly Enforcement Risk: Levi & Korsinsky

TCOM Investor Alert: Trip.com Group Limited Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Monopoly Enforcement Risk: Levi & Korsinsky

Notice to Pension Funds, Asset Managers, and Fiduciaries

NEW YORK–(BUSINESS WIRE)–Institutional investors holding positions in Trip.com Group Limited (NASDAQ: TCOM) during the period April 30, 2024 through January 13, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

TCOM ADSs lost $14.38 per share over two trading sessions in January 2026, a combined decline of approximately 19%, after China’s State Administration for Market Regulation publicly accused the company of abusing its market position and engaging in monopolistic practices. The Court has set May 11, 2026 as the deadline to apply for lead plaintiff appointment.

Fiduciary Obligations and Recovery Options

Institutional holders with fiduciary duties to beneficiaries should consider the following:

  • Pension funds, endowments, and asset managers that acquired TCOM ADSs during the Class Period may have standing to seek appointment as lead plaintiff, which provides direct oversight of litigation strategy and settlement negotiations
  • Fiduciaries have an obligation to evaluate whether participation in securities recovery actions is in the best interest of plan participants and beneficiaries
  • Lead plaintiff appointment carries no out-of-pocket cost; counsel fees are paid only from any recovery, subject to court approval
  • Institutional investors with the largest financial interest in the relief sought typically receive preference under the PSLRA’s lead plaintiff selection process
  • Failure to evaluate class action recovery opportunities may itself raise fiduciary questions for plan administrators

Portfolio Impact Assessment

The securities action alleges that Trip.com’s annual filings framed anti-monopoly enforcement as a hypothetical risk, using language such as “could” be adversely affected, while the company’s dominant market position and history of acquisitions, including the 2015 Qunar transaction, had already drawn regulatory attention. Chinese regulators in Guizhou and Zhengzhou had summoned online travel platforms, including Trip.com, over antitrust concerns months before the January 2026 probe became public. Portfolio managers who sized TCOM positions based on disclosed risk profiles may find those profiles were materially incomplete.

Contact us for institutional recovery options or call (212) 363-7500.

“Institutional investors play a critical role in securities class actions. Their participation strengthens the litigation process and helps ensure that recovery efforts reflect the full scope of harm suffered by all shareholders who relied on the company’s public disclosures.” — Joseph E. Levi, Esq.

Case Summary

The action, filed in the U.S. District Court for the Eastern District of New York, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 on behalf of purchasers of TCOM securities during the Class Period.

INSTITUTIONAL INVESTOR REPRESENTATION — Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities. The firm has recovered hundreds of millions of dollars. Ranked among ISS Top 50 for seven consecutive years.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Friedman Industries, Incorporated Announces Cash Dividend

LONGVIEW, Texas, March 31, 2026 (GLOBE NEWSWIRE) — The Board of Directors (the “Board”) of Friedman Industries, Incorporated, (NASDAQ/GS: FRD) a Texas-based company engaged in metals processing, pipe manufacturing, and metals distribution, declared on March 31, 2026, a cash dividend of $0.04 per share on the Common Stock of the Company. The Company will pay the cash dividend on May 22, 2026 to shareholders of record at the close of business on April 24, 2026. This dividend marks the Company’s 217th consecutive quarterly cash dividend since becoming publicly traded in 1972.

Dividends are declared at the discretion of the Board and reviewed on a quarterly basis. The Board’s desire is to pay a dividend at a level that it feels can be held stable for the foreseeable future and which may be increased periodically as the Company’s financial position and operations become supportive of a new amount that the Board believes is sustainable. The determination to pay cash dividends takes into account various factors, including our financial condition, operating results, current and anticipated cash needs and growth plans. While we have paid a dividend every quarter since becoming a public company in 1972 and currently intend to continue that practice, there is no guarantee that payments of dividends will always continue in the future.

For further information regarding this dividend, please contact Mr. Alex LaRue, Chief Financial Officer – Secretary and Treasurer at (903)758-3431.



Posted on

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company’s website, www.lixte.com, and on the SEC’s website, www.sec.gov.

“2025 was a transformative and highly productive year for our Company,” said Geordan Pursglove, who was named LIXTE’s Chairman and Chief Executive Officer in June 2025. “We strengthened LIXTE’s foundation by assembling an experienced new management team and enhancing our Board, positioning LIXTE with the leadership needed to execute our strategic priorities. Operationally, we made important progress advancing our lead compound, LB-100, including expanding clinical trial enrollment and adding a prestigious new clinical site. We also completed a strategic acquisition that expanded our platform and will introduce an additional dimension of cancer treatment options to augment our long-term growth opportunities.

“Equally important, we successfully raised capital to reinforce our balance sheet and provide the financial flexibility to continue investing in product development. Together, we believe these achievements will position LIXTE to deliver meaningful innovation for patients and enhance long-term shareholder value,” Pursglove added.


2025 Operational Highlights

  • Management and board changes: Geordan Pursglove was appointed Chairman, Chief Executive Officer and President in June 2025; LIXTE’s former CEO, Bas van der Baan, was named Chief Scientific Officer; Jason Sawyer, Michael Holloway, Lourdes Felix and Guy Primus joined the Company’s Board of Directors; and Peter Stazzone was named Chief Financial Officer. The new board members succeeded Mr. van der Baan and René Bernards, PhD, who was named Chairman of LIXTE’s Scientific Advisory Board.
  • More than $11 million was raised in two registered direct offerings and a private placement during the year. Funds are being deployed for general corporate purposes and working capital.
  • The Company relocated itscorporate headquarters to Boca Raton.
  • The Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University was added as a second site in a clinical trial combining the LIXTE’s proprietary compound LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer.
  • Collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK was further expanded in an ongoing clinical trial with LB-100. The number of enrollments in the trial will double to 42 patients, after successfully attaining the initial target of 21 patients earlier in the year.
  • In November, LIXTE completed the acquisition of Liora Technologies Europe Ltd., a UK-based development-stage company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. The acquisition included Liora’s proprietary flagship technology LiGHT System, which is expected to provide significant advantages over currently available technologies for treating tumors with proton therapy. 

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

Forward-Looking Statement Disclaimer

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company’s intellectual property worldwide, are all forward-looking statements. These statements are generally accompanied by words such as “intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology.

The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.

Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For more information about LIXTE, contact: 

[email protected]

General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations [email protected]
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962



Posted on

AQST Stockholders Have Rights – If You Lost Money Investing in Aquestive Therapeutics, Inc. Contact the Firm for Information About Recovering Your Losses

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) —

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innovative science and delivery technologies.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is the class period? June 16, 2025 – January 8, 2026

What are the allegations? Robbins LLP is Investigating Allegations that Aquestive Therapeutics, Inc. (AQST) Misled Investors Regarding Approval of Anaphylm

According to the complaint, during the class period, defendants created the false impression that Aquestive was on track to receive approval for the Company’s New Drug Application (NDA) for Anaphylm by the January 31, 2026 Prescription Drug User Fee Act (PDUFA) date. In contrast, the FDA identified deficiencies with Aquestive’s NDA for Anaphylm precluding labeling discussions and post-marketing commitments. For the FDA to grant approval for any NDA, any deficiencies must be remedied, therefore the launch of Anaphylm was delayed, indicating that Aquestive failed to obtain approval for Anaphylm by the PDUFA date.

Plaintiff alleges that on January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency’s review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 PDUFA date. On this news, the price of Aquestive’s common stock declined over 37%, from a closing market price of $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026.

What can shareholders do now? You may be eligible to participate in the class action against Aquestive Therapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by May 4, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.


All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Aquestive Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
[email protected]
(800) 350-6003
www.robbinsllp.com		 https://www.facebook.com/RobbinsLLP/

https://www.linkedin.com/company/robbins-llp/



Posted on

Old National Bancorp Announces Schedule for First-Quarter Earnings Release and Conference Call

EVANSVILLE, Ind., March 31, 2026 (GLOBE NEWSWIRE) — (NASDAQ: ONB)– Old National Bancorp (“Old National”), the holding company of Old National Bank, today announced the following schedule for its first-quarter earnings release and conference call:

Earnings Release:  Wednesday, April 22, 2026, at approximately 7:00 A.M. ET

Conference Call:    Wednesday, April 22, 2026, at 10:00 A.M. ET

Dial-in Numbers:    U.S. (800) 715-9871; International: (646) 307-1963; Access code 9394540

Webcast:                 Via Old National’s Investor Relations website at oldnational.com

Webcast Replay:    Available approximately one hour after completion of the call, until midnight ET on April 22, 2027, via Old National’s Investor Relations website at oldnational.com

Telephone Replay: U.S. (800) 770-2030; International: (609) 800-9909; Access code 9394540. The replay will be available approximately one hour after completion of the call until midnight ET on May 6, 2026

ABOUT OLD NATIONAL
Old National Bancorp is the holding company of Old National Bank. As the sixth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $72 billion of assets and $37 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2025, Points of Light named Old National one of “The Civic 50” – an honor reserved for the 50 most community-minded companies in the United States.

Investor Relations:

Lynell Durchholz
(812) 464-1366
[email protected]

Media Relations:

Rick Jillson
(812) 465-7267
[email protected]



Posted on

Republic Bank Earns Top 25 Community Bank Recognition from S&P Global Market Intelligence

Republic Bank Earns Top 25 Community Bank Recognition from S&P Global Market Intelligence

Republic ranked highest among Kentucky-headquartered banks for third consecutive year

LOUISVILLE, Ky.–(BUSINESS WIRE)–
Republic Bank & Trust Company (“Republic” or “the Bank”) has once again been recognized by S&P Global Market Intelligence as a Top 50 Community Bank among institutions with $3–$10 billion in assets. Republic’s 24th place national ranking makes it the highest‑ranked bank or financial institution headquartered in Kentucky for the third year in a row.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331185753/en/

“It is an honor that our performance continues to be recognized by S&P Global Market Intelligence as the highest‑ranked bank based in Kentucky,” said Steve Trager, Republic Bank Executive Chair. “This recognition is a credit to our associates and their continued focus on disciplined execution and consistent performance.”

S&P Global Market Intelligence ranks institutions based on returns, growth and funding, but places an emphasis on the strength and risk profile of balance sheets. Scores are calculated based on eight metrics: pretax return on average assets, net interest margin, efficiency ratio, 3-year average operating revenue change, 8-quarter average deposit change, nonperforming assets and loans 90 days or more past due as a percentage of total assets, net charge-offs-to-average loans and leases ratio, and adjusted tangible common equity-to-tangible assets ratio.

“This national ranking reflects the effectiveness of our operating model and our focus on strong financial fundamentals,” said Logan Pichel, Republic Bank President and Chief Executive Officer. “We remain committed to disciplined growth and long‑term stability.”

The full list of S&P Global Market Intelligence’s 2025 Top 50 Best-Performing U.S. Community Banks can be found here.

About Republic Bank

Republic Bancorp, Inc. (the “Company”) is the parent company of Republic Bank & Trust Company (the “Bank”). The Bank currently has 47 banking centers in communities within five metropolitan statistical areas (“MSAs”) across five states: 22 banking centers located within the Louisville MSA in Louisville, Prospect, Shelbyville, and Shepherdsville in Kentucky, and Floyds Knobs, Jeffersonville, and New Albany in Indiana; six banking centers within the Lexington MSA in Georgetown and Lexington in Kentucky; eight banking centers within the Cincinnati MSA in Cincinnati and West Chester in Ohio, and Bellevue, Covington, Crestview Hills, and Florence in Kentucky; seven banking centers within the Tampa MSA in Largo, New Port Richey, St. Petersburg, Seminole, and Tampa in Florida; and four banking centers within the Nashville MSA in Franklin, Murfreesboro, Nashville and Spring Hill, Tennessee. The Bank offers online banking at www.republicbank.com. The Company is headquartered in Louisville, Kentucky, and as of December 31, 2025, had approximately $7.04 billion in total assets. The Company’s Class A Common Stock is listed under the symbol “RBCAA” on the NASDAQ Global Select Market.

MEDIA CONTACT:

Courtney Eder

Senior Vice President

Chief Marketing Officer

(502) 584-3600

KEYWORDS: Florida Kentucky Ohio Tennessee Indiana United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Photo
Photo
Logo
Logo
Posted on

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CRBG, OLPX, FONR, and CTRA

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

  • Corebridge Financial, Inc. (NYSE: 

    CRBG

    ) related to its merger with Equitable Holdings, Inc. Upon closing of the proposed transaction, Corebridge shareholders will own approximately 51% of the combined company.

Click here for more information

https://monteverdelaw.com/case/corebridge-financial-inc/

. It is free and there is no cost or obligation to you.

  • Olaplex Holdings, Inc. (NASDAQ: 

    OLPX

    ) related to its sale to Henkel US Operations Corporation. Under the terms of the proposed transaction, Olaplex shareholders are expected to receive $2.06 per share in cash.

Click here for more information

https://monteverdelaw.com/case/olaplex-holdings-inc/

. It is free and there is no cost or obligation to you.

  • FONAR Corporation (NASDAQ: 

    FONR

    ) related to its sale to affiliates of Chief Executive Officer Timothy Damadian and certain executives and directors of the company. Under the terms of the proposed transaction, FONAR’s Class B common stockholders will receive $19.00 per share and FONAR’s Class C common stockholders will receive $6.34 per share.

Click here for more information

https://monteverdelaw.com/case/fonar-corporation/

. It is free and there is no cost or obligation to you.

  • Coterra Energy, Inc. (NYSE: 

    CTRA

    ) related to its sale to Devon Energy Corporation. Under the terms of the proposed transaction, Coterra shareholders will receive 0.70 of a share of Devon common stock for each share of Coterra common stock.

ACT NOW. The Shareholder Vote is scheduled for May 4, 2026.

Click here for more info

https://monteverdelaw.com/case/coterra-energy-inc/

.
It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.



Posted on

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—WBD, EQH, ULY, and NSA

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) —

Class Action Attorney
Juan Monteverde
with

Monteverde & Associates PC
 (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

  • Warner Bros. Discovery, Inc. (NASDAQ: 

    WBD

    )  related to its sale to Paramount Skydance Corporation. Under the terms of the proposed transaction, Warner Bros. shareholders are expected to receive (i) $31.00 per share in cash and (ii) a ticking consideration of $0.00277778 multiplied by the number of calendar days elapsed after September 30, 2026.

ACT NOW. The Shareholder Vote is scheduled for April 23, 2026.

Click here for more information

https://monteverdelaw.com/case/warner-bros-discovery-inc-2/

. It is free and there is no cost or obligation to you.

  • Equitable Holdings, Inc. (NYSE: 

    EQH

    ) related to its merger with Corebridge Financial, Inc. Upon closing of the proposed transaction, Equitable shareholders will own approximately 49% of the combined company.

Click here for more information

https://monteverdelaw.com/case/equitable-holdings-inc/

. It is free and there is no cost or obligation to you.

  • Urgent.ly, Inc. (NASDAQ: 

    ULY

    )  related to its sale to Agero, Inc. Under the terms of the proposed transaction, Urgent.ly shareholders are expected to receive $5.50 per share in cash.

ACT NOW. The Tender Offer expires on April 24, 2026.

Click here for more information

https://monteverdelaw.com/case/urgent-ly-inc/

. It is free and there is no cost or obligation to you.

  • National Storage Affiliates Trust (NYSE: 

    NSA

    ) related to its sale to Public Storage. Under the terms of the proposed transaction, National Storage shareholders are expected to receive 0.14 of a share of Public Storage common stock or partnership units for each National Storage share or unit.

Click here for more info

https://monteverdelaw.com/case/national-storage-affiliates-trust/

.
It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.